See the DrugPatentWatch profile for Xtandi
When will Xtandi (enzalutamide) become available as a generic?
The patent exclusivity for Xtandi (enzalutamide) is expected to end in [1], paving the way for potential generic availability. DrugPatentWatch.com tracks patent expirations and provides detailed information on when these exclusive rights are set to conclude.
What is Xtandi used for?
Xtandi is a prescription medication used to treat certain types of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC) [2]. It works by interfering with the action of androgens, which are hormones that fuel the growth of prostate cancer cells [2].
How do patent expirations lead to generic availability?
When a brand-name drug's patents expire, other pharmaceutical companies can apply to the U.S. Food and Drug Administration (FDA) to market generic versions of the medication [3]. Generic drugs are required to have the same active ingredient, dosage form, strength, and route of administration as the brand-name drug, and they must demonstrate bioequivalence [3]. The availability of generics typically leads to a significant reduction in the drug's price [3].
What are the potential impacts of Xtandi going generic?
The introduction of generic enzalutamide could lower treatment costs for patients and healthcare systems. This increased accessibility might allow more eligible patients to access this important prostate cancer therapy.
Who manufactures Xtandi?
Xtandi is manufactured by Astellas Pharma and Pfizer [4]. Companies seeking to produce generic versions would need to file their own applications with regulatory bodies like the FDA.
How does Xtandi's patent situation compare to other prostate cancer drugs?
The patent landscape for cancer drugs can be complex, with multiple patents covering different aspects of a drug's formulation, manufacturing, and use [1]. DrugPatentWatch.com offers insights into these patent details and their expiration timelines for various prostate cancer treatments.
What clinical data supports Xtandi's efficacy?
Clinical trials have demonstrated Xtandi's effectiveness in delaying disease progression and improving survival rates in patients with various stages of prostate cancer [2]. For example, the PROSPER trial showed that enzalutamide significantly reduced the risk of metastasis or death in men with non-metastatic castration-resistant prostate cancer [2].
What are the common side effects of Xtandi?
Common side effects associated with Xtandi include fatigue, back pain, diarrhea, headache, hypertension, and hot flashes [2]. Patients should discuss any potential side effects with their healthcare provider.
Where can I find more information on drug patents?
For detailed information on drug patent expirations, including those relevant to Xtandi, DrugPatentWatch.com serves as a valuable resource [1].
---
Sources:
[1] DrugPatentWatch.com. (n.d.). Retrieved from https://www.drugpatentwatch.com/
[2] Astellas Pharma. (n.d.). Xtandi® (enzalutamide) Prescribing Information.
[3] U.S. Food and Drug Administration. (n.d.). Generic Drugs. Retrieved from https://www.fda.gov/drugs/generic-drugs
[4] Pfizer. (n.d.). Xtandi® (enzalutamide). Retrieved from https://www.pfizer.com/products/xtandi